Vertex completes $10 billion Crinetics acquisition, its largest deal ever

Overview

Updated Sep 2

Vertex Pharmaceuticals closed its $10 billion acquisition of Crinetics Pharmaceuticals on September 1, 2026, the largest deal in the company's history. Crinetics shareholders received $85 per share in cash, and the San Diego biotech is now a wholly owned Vertex subsidiary.

The deal gives Vertex PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly, launched in the U.S. and approved in the EU. It also adds atumelnant, an oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 for congenital adrenal hyperplasia and Phase 2 for Cushing's syndrome. Vertex expects the deal to add to its non-GAAP operating income in 2029.

Why it matters

The deal makes Vertex a major endocrine-disease player, adding an approved acromegaly drug and late-stage candidates for two rare hormonal disorders.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$85

Cash price per Crinetics share

Every Crinetics share converted into the right to receive $85 cash when the merger closed.

$10.0B

Total equity value

Approximate equity value of the deal announced July 6, 2026.

$8.8B

Net of estimated cash acquired

Approximate purchase price after subtracting Crinetics' cash on hand.

$5B+

Projected combined peak annual revenue

Vertex's projection for PALSONIFY and atumelnant at peak sales.

$4.9B

Vertex's prior record acquisition

The April 2024 Alpine Immune Sciences deal; Crinetics is more than double that size.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

R. Scott Struthers

Crinetics co-founder and chief executive officer until the acquisition closed

Resigned from the board when the merger closed September 1, 2026

Charles Wagner

Vertex Pharmaceuticals chief financial officer

Became sole director and president of the Crinetics subsidiary at closing

Reshma Kewalramani

Vertex Pharmaceuticals chief executive officer

Leading Vertex's expansion beyond cystic fibrosis

Organizations Involved

Vertex Pharmaceuticals

Public biopharmaceutical company

Acquirer; Crinetics is now a wholly owned subsidiary

Boston-based biopharmaceutical company whose cystic fibrosis drugs generate most of its revenue.

Crinetics Pharmaceuticals

Public biopharmaceutical company

Acquired; delisted from Nasdaq; operates as a Vertex subsidiary

San Diego-based biopharmaceutical company focused on oral small-molecule therapies for endocrine diseases.

Timeline

July 2026 September 2026

5 events Latest: September 1st, 2026 · 1 week ago

Tap a bar to jump to that date

September 2026
Vertex closes $10 billion Crinetics acquisition
Latest Acquisition

The merger took effect. Crinetics shares converted to $85 cash each and were delisted from Nasdaq; unvested options and restricted stock units vested and were cashed out.
September 1st, 2026
Vertex announces executive leadership expansion
Corporate

Vertex announced an expanded executive leadership team in its closing announcement, alongside the integration of Crinetics' pipeline.
September 1st, 2026
August 2026
Crinetics shareholders approve the acquisition
Approval

Stockholders voted to approve the merger at a special meeting, clearing the final shareholder condition to close.
August 28th, 2026
Antitrust clearances received for Crinetics deal
Regulatory

The U.S. antitrust waiting period expired August 12, and approvals from Austria, Germany, and Australia were in hand by August 13. Australia's waiting period ended August 27.
August 13th, 2026
July 2026
Vertex and Crinetics announce $10 billion merger deal
Announcement

Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in total equity value. Both boards approved unanimously.
July 6th, 2026

Scenarios

Vertex confirms Crinetics deal is accretive by 2029

Likely Resolves by Feb 15, 2030

Discussed by: Vertex management, which guided to 2029 accretion in the closing announcement; Clinical Trial Vanguard's analysis of the integration timeline

Vertex guided that the acquisition would add to non-GAAP operating income, a profit measure adjusted for items like acquisition costs and stock compensation, starting in 2029. Hitting that target requires PALSONIFY sales to grow in the U.S. and Europe and atumelnant's trials to stay on schedule. Vertex's quarterly earnings reports will show whether the trajectory holds.

Atumelnant posts positive Phase 3 results in congenital adrenal hyperplasia

Possible Resolves by Q2 2028

Discussed by: MedCity News and Clinical Trial Vanguard, both of which analyzed atumelnant's role in the deal's value

Atumelnant is the biggest future value driver in the deal. It is a once-daily oral ACTH receptor antagonist in Phase 3 for congenital adrenal hyperplasia, a rare disorder now treated with high-dose glucocorticoids. A positive readout would validate the $10 billion price; a negative one would erase most of the deal's projected upside.

Vertex writes down Crinetics assets after a stumble

Unlikely Resolves by End of 2028

Discussed by: Clinical Trial Vanguard, whose early analysis focused on the integration risk of the deal

If PALSONIFY's launch stalls or atumelnant fails in the clinic, Vertex could record an impairment on the Crinetics purchase. Pfizer set the precedent: it wrote down much of its $5.4 billion Global Blood Therapeutics deal after withdrawing the sickle cell drug Oxbryta in 2024. Vertex's SEC filings would reveal any such charge.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

August 2022

Pfizer acquires Global Blood Therapeutics (2022)

Pfizer agreed to pay $5.4 billion for Global Blood Therapeutics, gaining Oxbryta, an approved sickle cell drug with growing sales.

Then

The deal closed in October 2022 and made Pfizer a player in sickle cell treatment.

Now

In September 2024, Pfizer withdrew Oxbryta worldwide after trial data showed higher death rates among treated patients, erasing much of the deal's value.

Why this matters now

The cautionary case for the Crinetics deal: a rare-disease drug's commercial value can vanish after closing, which is why atumelnant's Phase 3 results carry so much weight.

December 2022

Amgen acquires Horizon Therapeutics (2023)

Amgen agreed to pay $27.8 billion for Horizon Therapeutics, whose portfolio centered on rare autoimmune drugs Tepezza and Krystexxa. The U.S. Federal Trade Commission sued to block the deal.

Then

The deal closed in October 2023 after Amgen settled the FTC lawsuit over drug bundling practices.

Now

The case showed regulators will scrutinize large rare-disease acquisitions but rarely manage to block them.

Why this matters now

Like Amgen, Vertex paid a premium for a rare-disease portfolio; the Crinetics deal cleared its regulatory clearances in under two months.

April 2024

Vertex acquires Alpine Immune Sciences (2024)

Vertex agreed to pay $4.9 billion for Alpine Immune Sciences, gaining povetacicept, a late-stage drug for IgA nephropathy and other autoimmune diseases. The deal closed weeks later.

Then

The deal added a Phase 3 autoimmune drug to Vertex's pipeline and marked its first major diversification beyond cystic fibrosis.

Now

It established Vertex's pattern of buying late-stage clinical assets rather than building new drug programs from scratch.

Why this matters now

Crinetics follows the same playbook at more than twice the price, and Alpine is the benchmark for how Vertex integrates an acquired pipeline.